Proteostasis Therapeutics announced results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19. PTI-129 is a pre-clinical, once-daily, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response (UPR).
Upon infection, coronaviruses hijack the host cell endoplasmic reticulum (ER) to quickly produce a larger quantity of misfolding-prone viral glycoproteins. The accumulation of misfolded and unfolded proteins in the ER causes ER stress and induces the UPR. In in vitro studies conducted at Calibr, the drug discovery division of Scripps Research, PTI-129 demonstrated the potential to reduce viral protein production in host cells by activating the adaptive branches of the UPR pathway and reducing the levels of misfolded proteins.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"The ongoing COVID-19 pandemic is a public health crisis that demands the investigation of all possible avenues of resolution," said Meenu Chhabra, President and CEO of Proteostasis. "We are exploring ways to further our understanding of PTI-129's potential in fighting COVID-19, and are seeking support from governmental agencies to accelerate this program."
"The urgent need to develop effective treatments against COVID-19 is a global priority, and Calibr is committed to studying a broad spectrum of compounds and pathways, such as the UPR modulator, PTI-129, in the fight against this disease," said Arnab Chatterjee, PhD, Vice President of Medicinal Chemistry at Calibr.